Lenalidomide plus R-GDP (R2-GDP) in Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Final Results of the R2-GDP-GOTEL Trial and Immune Biomarker Subanalysis.

Clin Cancer Res · 2022 · PMC9433956 · PMID 35727601

Europe PMC DOI

hedged sentence

0.1180

closest p · 2.4× alpha

0.1180

boldest claim

The sentences

did not reach statistical significanceP = 0.118not close (p > 0.1)

Although a trend was observed for worse response within increasing IPI, it did not reach statistical significance, either in the whole population ( P = 0.118; Supplementary Table S4) or in the sub-cohort with primary refractory disease ( P = 0.242; Supplementary Table S5).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.